TY - JOUR
T1 - A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder
AU - Krupski, T.
AU - Moskaluk, C.
AU - Boyd, J. C.
AU - Theodorescu, Dan
PY - 2000
Y1 - 2000
N2 - Objective: To determine, in patients newly diagnosed with bladder cancer, whether p53, epidermal growth factor receptor (EGPR), microvessel density (MVD), urinary bladder tumour antigen (BTA TRAK(TM), Bion Diagnostic Sciences, Redmond, WA) and cytology were predictive of clinical stage, evaluated as a function of the clinical stage obtained at transurethral resection of the bladder tumour with and without the addition of clinical grade, a known strong predictor of clinical stage. Patients and methods: Between December 1997 and September 1998, 22 men and seven women with a cystoscopic diagnosis of urothelial bladder carcinoma were prospectively enrolled in the study. Urine was collected for cytological and BTA TRAK evaluation before transurethral resection. Tumour grade and clinical stage were obtained from the transurethral resection specimen. MVD was evaluated by computerized calculations of 'optimal MVD' (OMVD) and 'area-weighted MVD' (AWMVD) while p53 and EGFR information was obtained by manual immunohistochemical techniques: 21 patients had sufficient tissue for all immunohistochemical assessments and comprised the study group. Univariate and multivariate comparisons were carried out to determine the contribution of each variable to the prediction of clinical stage. Results: Although there was a trend, cytological analysis and p53 and MVD immunoreactivity did not significantly correlate with clinical stage. while tumour grade, BTA TRAK and EGFR immunoreactivity did. In a univariate analysis, tumour grade and BTA TRAK were related to clinical stage. In a multivariate analysis, grade was the single best predictor of clinical stage. This analysis also showed that the addition of BTA TRAK and MVD information to grade incrementally improved the predictive ability of grade. Conclusions: This pilot study suggests that BTA TRAK and MVD contribute incremental information to tumour gr;rdc in predicting the clinical stage of urothelial carcinomas of the bladder: grade remains the most important predictor. These results suggest that further work with BTA TRAK and MVD in more patients and on biopsy material obtained during clinic cystoscopy is warranted for the future development of less invasive methods of identifying patients with invasive bladder cancer.
AB - Objective: To determine, in patients newly diagnosed with bladder cancer, whether p53, epidermal growth factor receptor (EGPR), microvessel density (MVD), urinary bladder tumour antigen (BTA TRAK(TM), Bion Diagnostic Sciences, Redmond, WA) and cytology were predictive of clinical stage, evaluated as a function of the clinical stage obtained at transurethral resection of the bladder tumour with and without the addition of clinical grade, a known strong predictor of clinical stage. Patients and methods: Between December 1997 and September 1998, 22 men and seven women with a cystoscopic diagnosis of urothelial bladder carcinoma were prospectively enrolled in the study. Urine was collected for cytological and BTA TRAK evaluation before transurethral resection. Tumour grade and clinical stage were obtained from the transurethral resection specimen. MVD was evaluated by computerized calculations of 'optimal MVD' (OMVD) and 'area-weighted MVD' (AWMVD) while p53 and EGFR information was obtained by manual immunohistochemical techniques: 21 patients had sufficient tissue for all immunohistochemical assessments and comprised the study group. Univariate and multivariate comparisons were carried out to determine the contribution of each variable to the prediction of clinical stage. Results: Although there was a trend, cytological analysis and p53 and MVD immunoreactivity did not significantly correlate with clinical stage. while tumour grade, BTA TRAK and EGFR immunoreactivity did. In a univariate analysis, tumour grade and BTA TRAK were related to clinical stage. In a multivariate analysis, grade was the single best predictor of clinical stage. This analysis also showed that the addition of BTA TRAK and MVD information to grade incrementally improved the predictive ability of grade. Conclusions: This pilot study suggests that BTA TRAK and MVD contribute incremental information to tumour gr;rdc in predicting the clinical stage of urothelial carcinomas of the bladder: grade remains the most important predictor. These results suggest that further work with BTA TRAK and MVD in more patients and on biopsy material obtained during clinic cystoscopy is warranted for the future development of less invasive methods of identifying patients with invasive bladder cancer.
KW - Angiogenesis
KW - BTA
KW - Bladder neoplasm
KW - Cytology
KW - Epidermal growth factor receptor
KW - Prognosis
KW - Tumour markers
KW - p53
UR - http://www.scopus.com/inward/record.url?scp=0034079473&partnerID=8YFLogxK
U2 - 10.1046/j.1464-410X.2000.00676.x
DO - 10.1046/j.1464-410X.2000.00676.x
M3 - Article
C2 - 10848689
AN - SCOPUS:0034079473
SN - 1464-4096
VL - 85
SP - 1027
EP - 1032
JO - BJU International
JF - BJU International
IS - 9
ER -